Monoclonal antibodies have emerged as an important class of therapeutics in oncological and autoimmune diseases due to their several attractive properties, such as high binding affinity and specificity. However, it has recently become clear that antibodies recovered from serum show a significantly decreased potency owing to various reasons, including deamidation, oxidation, fragment antigen binding (Fab) exchange, and disulfide shuffling. Fab exchange and disulfide shuffling result because of the instability of disulfides in serum. Herein, we reported a 'one-pot' stapling strategy using isobutylene motifs to stabilise the interchain disulfides of antibodies. This general method was applied to a Fab fragment of the anti-HER2 antibody. The stapled Fab was completely stable in the presence of biological thiols. The approach was further applied to two different full-length IgGs, trastuzumab and rituximab, under mild and biocompatible conditions. The binding affinity of the antibody was enhanced, relative to its native form, after being stapled. The stapled structure maintained its effector functions and behaved similarly to its native form in vivo. This work provides a straightforward and scalable method for the stabilisation of antibodies in various formats. † Electronic supplementary information (ESI) available. See
Introduction
In 1975, the monoclonal antibody (mAb) technique was developed by Köhler, Milstein, and Jerne, who shared the 1984 Nobel Prize in Physiology or Medicine for the discovery. Since then, mAbs have revolutionised the treatment of a wide range of diseases, including cancer, chronic inflammation, cardiovascular, transplantation and infectious diseases. 1 With recent advances in the expression of antibodies, a wide range of mAbs have reached the market. 2 To date, over 80 antibody therapeutics have been approved by the European Medicines Agency and the United States Food and Drug Administration (FDA) and numerous others are at various stages of research and development. 3 Recently, Sir Gregory Winter was jointly awarded the 2018 Nobel Prize in Chemistry for his pioneering work in the use of phage display for the directed evolution of antibodies, with the aim of producing new pharmaceuticals. A variety of important properties of mAbs have contributed to their success as therapeutics, such as a high binding affinity and specificity, high conformational stability and colloidal stability, and relative ease of manufacturing. 4 Antibodies, immunoglobulins (Ig), are classified into five classes on the basis of the constant region of the heavy chain, IgA, IgD, IgE, IgG and IgM. 5 The most relevant for therapeutics is IgG, which has four subclasses, IgG1-4. 6 The IgG monomer, a bivalent molecule, comprises two identical heavy chains and two identical light chains that are linked by interchain disulfide bonds. Each of the heavy and light chains contain structural domains that resemble antibody folds made up of two beta sheets linked by intrachain disulfides. 7 The intrachain disulfides in both heavy and light chains for all four types of IgG subclasses are similar. IgG1 and IgG4 have two interchain disulfides between their heavy chains, whereas IgG2 and IgG3 have four and eleven disulfides, respectively. 1 Among all the disulfides, the interchain disulfides are more solvent exposed and less stable relative to the intrachain disulfides that are buried between the two layers of anti-parallel β-sheet structures within each domain. Therefore, non-standard disulfide bond patterns, trisulfide bonding, and thioether linkage formation may occur after antibody assembly. 8 The fragment antigen binding (Fab) arm exchange, in which halfantibodies from one therapeutic IgG4 molecule exchange with those of another endogenous molecule, is one of the highly undesirable events. 9 This deviation has profound effects on the therapeutic efficacy of these molecules, including adverse events, and pharmacokinetic and pharmacodynamic profiles. The instability of disulfides is also found in IgG2 subclasses where its activity is modulated by disulfide shuffling in serum. 10 Three different isomers with different interchain disulfide patterns possess significant differences in activity. Although mAb is one of the most stable and resistant forms against changes to their environment, even a small deviation can severely affect their quality, efficacy and safety in the clinic. Therefore, close attention should be paid to these deviations when generating and administering mAbs. In this regard, stapled disulfides might be able to tackle this problem and provide more stable mAbs. Although several approaches have been reported for the stapling of polypeptides 11 and antibodies, 12 such as using dibromopyridazonedione 13 and dithiophenolmaleimide, 14 there is still a demand for simple, efficient and scalable techniques to chemically stabilise mAbs using small reagents.
Previously, we reported a 'one-pot' isobutylene macrocyclization strategy [with tris(2-carboxyethyl)phosphine (TCEP) as the reducing agent] for thiol-containing peptides. 15 Cyclic peptides possess significantly enhanced membrane permeability and binding affinity. Herein, we applied and optimised this strategy to mAbs and investigated the stability, binding affinity, and effector functions such as the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). With this method, the disulfides of antibodies and derivatives can be reduced by TCEP and efficiently stapled with 1,3-dibromo-2-methylpropane (1).
Results and discussion

Stapling of the Fab fragment of anti-HER2 antibody
We commenced our investigation with the Fab fragment of anti-HER2 antibody that consists of one solvent exposed interchain disulfide. HER2 is a member of the human epidermal growth factor receptor family and is overexpressed in around 20-30% of breast-cancer tumours. In recent years, HER2 has become an important biomarker and target of therapy for breast cancer. 16 The first anti-HER2 monoclonal antibody, trastuzumab (Herceptin™), was approved by the FDA to treat HER2 receptor positive breast cancer in 1998. Herein, the Fab fragment was incubated with TCEP and the stapling reagent 1,3-dibromo-2-methylpropane (1) in both neutral PBS buffer ( pH 7.4) and alkaline sodium phosphate buffer ( pH 9.1) at room temperature overnight ( Fig. 1A) . Full conversion of the Fab fragment was observed by LC-MS with the generation of the expected mass ( Fig. 1B and Fig. S1-3 , ESI †). The co-incubation with TCEP and stapling reagent (1) in a 'one-pot' manner may be used to avoid disulfide scrambling. Moreover, the chemoselectivity of the disulfide stapling reaction was con-firmed through the reaction of the stapled product with Ellman's reagent [5,5′-dithiobis(2-nitrobenzoic acid)]. We found that the stapled Fab remained unchanged after incubation with Ellman's reagent at room temperature for 6 h which demonstrates that all free thiols had reacted ( Fig. S4 , ESI †). As mentioned above, disulfide bonds can be reduced and exchanged when circulating inside the human body as a result of the instability of disulfides; therefore, the stability of the stapled Fab obtained was tested with biological thiols, glutathione (GSH) and human plasma. After 24 hours of incubation with GSH or plasma at 37°C, the peak of the stapled Fab was still clearly shown in LC-MS ( Fig. 1B and Fig. S5 and 7, ESI †), which demonstrates that the stapled Fab is stable in the presence of biological thiols. In comparison, the native Fab was fully reduced in the presence of GSH under identical conditions ( Fig. S6 , ESI †).
Stapling of the full-length IgG antibody trastuzumab
After the successful application on the Fab fragment, the stapling method was then applied to the full-length antibody trastuzumab, which contains four interchain disulfide bonds: two between the light and heavy chains, and two between heavy chains ( Fig. 2A ). The reaction was initially conducted at 4°C to slow down the stapling and to avoid undesired cross-links. However, since only trace amounts of the stapled product were observed after 12 h, the reaction was warmed up to room temperature. After being incubated overnight, the peaks that were related to the reduced heavy and light chains disappeared in LC-MS, which indicates that the fragments have been covalently linked. Next, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was conducted under both non-reducing and reducing conditions. Similar bands were observed under non-reducing conditions (Fig. 2B , lane 1, native trastuzumab, and lanes 2 and 3, stapled trastuzumab), which shows that the antibody maintained its structural integrity after the stapling process. Under reducing conditions, the native antibody (lane 4) was reduced to heavy (∼50 kDa) and light chains (∼25 kDa). However, the stapled antibody (lane 4 and 5) was not reduced, which confirms that the antibody was stapled under reducing conditions. Furthermore, the stapled antibody also had a band ≈75 kDa, which corresponds to the half-stapled antibody, intrachain stapling of the cysteines on the same heavy chain ( Fig. S8 , ESI †). Because the two interchain disulfide bonds in the hinge region were close to each other, the stapling between the cysteines on the same heavy chain cannot be avoided. In this case, because it was not at the binding domain of the antibody, the affinity and kinetic properties were unaffected. Native mass spectrometry was also performed to validate the results ( Fig. S9 , ESI †). The mass of the stapled trastuzumab was 204 Da larger than that of native trastuzumab, which indicates that there were approximately four disulfides being stapled.
Evaluation of the binding affinity of stapled trastuzumab
To investigate whether the staple structure affected the binding affinity of antibodies, bio-layer interferometry (BLI) was used to investigate the binding kinetics of the native and stapled trastuzumab against the HER2 receptor. The binding between the antibody immobilized on the biosensor tip surface by means of a streptavidin (SA)-biotin interaction and the receptor HER2 in solution produced an increase in optical thickness at the biosensor tip, which resulted in a wavelength shift. Such a shift is a direct measurement of the thickness of antibodies and receptors. 17 Firstly, the native and stapled trastuzumab were biotinylated with a water-soluble NHS-ester biotinylation reagent NHS-PEG 4 -Biotin in order to be immobilised on the biosensor (Scheme S1, ESI †). Then the biotinylated antibodies were immobilized on the SA biosensors, dipped in the receptor HER2 solution and dissociated (Scheme S2 and Fig. S10 , ESI †). As shown in Fig. 2C , the derived K D constant of the stapled trastuzumab was smaller than the K D of the native trastuzumab, which indicates that the stapled trastuzumab has a slight improved binding affinity against receptor HER2 relative to the native species. Moreover, the binding ability of the stapled trastuzumab was also determined by flow-cytometric analysis against HER-2 positive human breast cancer cells (SKBR3) and HER-2 negative HPB-ALL cells, displaying the selected binding of both the antibodies towards HER-2 positive cells. Fig. 2D demonstrates the fluorescence-activated cell sorter (FACS) histograms by showing that the stapled structure did not disrupt the antigen recognition abilities of the antibody and was in fact equivalent to the native antibody.
Thermostability studies of stapled trastuzumab
Circular dichroism (CD) spectroscopy is a versatile technique towards the understanding of the stability and aggregation of monoclonal antibodies. We assessed the thermal stability of trastuzumab samples in solution, by recording the CD spectra at various temperatures from 25°C to 80°C. Monoclonal antibodies have a predominant β-sheet and random coil conformations. 18 A broad minimum at 218 nm in the far-UV CD spectra is indicative of a substantial presence of β-sheets. Besides the characterization of the trastuzumab secondary structure, we used CD spectroscopy to assess any conformational change as a result of the stapling chemistry. Heat may induce aggregation under conditions below the melting temperature of an antibody, which is why high temperatures coupled with spectroscopic techniques are often used to provide information about the structure.
Trastuzumab samples showed well-defined antiparallel β-pleated sheets with negative bands at 218 nm and positive bands close to 195 nm ( Fig. 3A and B ), which confirms that the secondary structure of the stapled antibody is not affected. Transitions in the CD spectra were monitored at different temperatures and the results suggest that the stapled trastuzumab displayed a greater degree of stability at higher temperatures (>75°C). In fact, a higher level of aggregation for native trastuzumab was seen after scanning this sample at 80°C, which was further verified by the considerable difference in the absorbance at 280 nm, which was scanned after denaturation (data not shown). The disordered proteins display very low ellipticity above 210 nm and negative bands near 195 nm, which is clearly observed in the native trastuzumab CD spectra at 80°C, in contrast to the stapled trastuzumab that maintains its secondary structure (Fig. 3C) . This difference in molar ellipticity at 80°C indicates a transition into a random coil for the native trastuzumab. Above 80°C, both native and stapled antibodies are considerably denatured (Fig. 3D ). To support these results, we also analysed the thermodynamic properties of the two antibodies by differential scanning fluorimetry (DSF). In a DSF experiment, temperature transitions were used to probe the interactions of a protein with Sypro® Orange, a fluorescent dye that binds to specific residues exposed during unfolding. 19 By using such a specific dye in DSF, we were able to identify key temperature transitions and protein stability features that allow for the analysis of molecular interactions. 19a The DSF data consisted of two transitions, centred around 68 and 80°C, with slightly different corresponding fluorescence intensities (Fig. 4A ). The transition temperatures (Tm 1 and Tm 2 ) for native and stapled trastuzumab samples were quite similar (Fig. 4B) , with a variation in the measured Tm 1 < 0.5°C. The determination of the melting temperatures was performed by the analysis of the first derivatives ( Fig. 4C and D), being Tm 2 = 81.8 ± 0.5°C and 82.4 ± 0.2°C for the native and stapled trastuzumab, respectively. The overall DSF patterns were comparable, although with a significantly higher area under the negative peak (−dF/dT ) in the first transition of the native trastuzumab (Fig. 4C) . These data suggest that the fluorescent probe undergoes a substantial increase in quantum yield as a result of the interaction with the exposed hydrophobic regions due to the higher degree of denaturation of the native trastuzumab.
It was previously described that differences between the spectra at the first transition with a large peak (close to 60°C) were ascribed mostly to the denaturation of the Fab segment in the case of immunoglobulin, whereas the gradual change between 70°C and 80°C is caused by denaturation of the Fc fragment. 20 It has also been reported that in the human myeloma IgG1 two transitions are also detected, with melting temperatures around 70°C for the Fab and Fc fragments and 66°C and 82°C for the Fc fragments. Based on these data, it was proposed that the CH 2 domain in the Fc fragment and the melting of the Fab fragment could be related to the first transition, whereas the second transition represented mainly the unfolding of the CH 3 domain in the Fc fragment. 21 Taking into account the correlation between the transitions observed and the domains that were related to those transitions, we observed that, for the stapled trastuzumab, the first transition had a smoothed fluorescence intensity, which means that the Fc fragments were likely not fully denatured.
Both CD and DSF data supported that the stapled trastuzumab possessed a higher degree of stability, though the antibodies have closer melting temperatures and, most importantly, the stapling strategy did not compromise the secondary structure of trastuzumab.
Effector-mediated functions of the stapled and native antibodies
The effector-mediated functions were evaluated with anti-CD20 mAb rituximab, which was first approved in 1997 for the treatment of chronic lymphocytic leukaemia and some types of non-Hodgkin lymphoma. Native rituximab was incubated with TCEP and 1,3-dibromo-2-methylpropane (1) at room temperature overnight. Then, analysis of the SDS-PAGE gel was conducted ( Fig. 5A ) that showed the same result as the stapling of trastuzumab, in which the antibody was fully stapled. With the stapled rituximab in hand, effector-mediated functions were further analysed.
Antibody-dependent cellular cytotoxicity (ADCC)
ADCC is effector-mediated cell death, which is activated when target cells (cancer cells) are co-cultured with Peripheral Blood Monocytes (PBMCs) in the presence of a full-length IgG antibody. Cell death is induced upon binding of the Fc stem of an antibody with FcRn of the immune cells, mainly natural killer (NK) cells. For stapled versus native rituximab, RAJI cells were co-cultured with freshly isolated human PBMCs. Cell death was similar to the native antibody, which suggests that the antibody stapling does not interfere with the Fc part of the antibody and helps it retain the effector functions as the native isoform (Fig. 5B ).
Complement-dependent cellular cytotoxicity (CDC)
Similar effects were seen for complement-mediated cell killing in which RAJI cells for rituximab ( Fig. 5C ) and SKBR3 cells for trastuzumab (Fig. 5D ) were co-cultured with 10% normal human serum and complement-mediated cell death was observed. Again, no stapled antibody maintained the profile as that of the native antibody.
In vivo pharmacokinetics of native and stapled antibodies in NOD-SCID mice
Because both forms of the antibody (stapled and native) displayed similar antigen binding ability and effector function properties, we investigated the pharmacokinetic potential of these in healthy mice. Equally dosed native and stapled trastuzumab were injected into disease free NOD-SCID mice and the stability of these antibodies was evaluated for about 28 days. Blood was drawn at the indicated time points and the plasma was used to assess the levels of intact antibodies using the HER2 extracellular domain capture-based enzyme linked immunosorbent assay (ELISA). The levels of intact antibodies reflected their stability and the total antibody clearance rate of both the formats was highly identical to native trastuzumab displaying a slightly lower clearance rate at day 7 when compared to the native form (Fig. 6) . These results hint towards the plausibility of higher accumulation of the stapled antibody when tested in tumour bearing mice due to the slight delay in the clearance rate.
Conclusions
A general disulfide re-bridging strategy for the stabilisation of antibodies with isobutylene motifs has been developed. This strategy can be applied to various antibodies and derivatives, such as Fab fragments, in a rapid and efficient 'one-pot' manner. The non-native stapled structure possesses a higher binding affinity than the native form, which is confirmed by both BLI and flow cytometry assays. Comprehensive stability studies were also conducted, which supported the idea that the stapled antibody had an enhanced thermostability and maintained its secondary structure. ADCC and CDC experiments confirmed that the stapled antibody maintained its effector-mediated functions. Moreover, in vivo pharmacokinetics demonstrated that the stabilities of both native and stapled antibodies in mice are similar. We believe that this efficient technique can be easily applied to antibody therapeutics and will completely remove the chance of disulfide exchange and shuffling. Furthermore, as a result of the enhanced stability, this technique may significantly reduce the cost of storing and transporting antibody therapeutics.
Experimental section
Stapling of anti-HER2 Fab
To a solution of anti-HER2 Fab in PBS solution buffer pH 7.4 (100 μL, 20 μM, 2 nmol) were added tris(2-carboxyethyl)phosphine hydrochloride (TCEP·HCl, 1 μL, 20 mM, 10 equiv.) and 3-bromo-2-bromomethyl-1-propene (1) in DMF (1 μL, 10 mM, 20 equiv.). The reaction was stirred at room temperature overnight. A 10 μL aliquot was analysed directly by LC-MS and full conversion was observed. Small molecules were removed from the reaction mixture by loading the sample onto a Zeba™ Spin Desalting Column (Thermo Scientific) previously equilibrated with pH 7.4 PBS solution buffer. The sample was eluted by centrifugation (2 min, 1000g). The protein solution was then flash frozen with liquid nitrogen and stored at −20°C.
Ellman's test of stapled Fab
To a solution of the stapled Fab in 1× PBS buffer (10 μL, 20 μM 0.2 nmol) was added 2 μL of a solution of Ellman's reagent (50 mM, 100 nmol, 500 equiv.). After being incubated at room temperature for 6 h, a 10 μL aliquot of the solution was analysed directly by LC-MS (ESI †). 
Stability test of stapled Fab
To a solution of native and stapled Fab in 1× PBS buffer (10 μL) was added GSH in H 2 O (1 μL, 60 mg mL −1 ) or human plasma (1 μL) and incubated at 37°C. After 24 h, a 10 μL aliquot of each was analysed directly by LC-MS (ESI †).
Stapling of IgG antibody (trastuzumab and rituximab)
To a solution of IgG antibody in 1× PBS solution (50 μL, 1.0 mg mL −1 ) were added TCEP·HCl in H 2 O (0.34 μL, 10 mM, 25 equiv.) and 3-bromo-2-bromomethyl-1-propene (1) in DMF (0.85 μL, 10 mM, 25 equiv.). The reaction mixture was incubated at 25°C for 12 h. Excess reagents were removed by diafiltration into PBS buffer by using Vivaspin 500 sample concentrators (GE Healthcare, 5 min, 15 000g, 30 kDa MWCO). The antibody solution was then flash frozen with liquid nitrogen and stored at −20°C.
SDS-PAGE gels
NuPAGE® Novex 4-12% Bis-Tris protein gels were used following the standard protocol. A Precision Plus Protein™ all blue pre-stained protein standard (10-250 kDa) was co-run to estimate protein weights. Non-reduced samples (7.5 μL) were mixed with NuPAGE® LDS sample buffer (2.5 μL, 4×) and heated at 70°C for 10 min. Reduced samples (6.5 μL) were mixed with NuPAGE® LDS sample buffer (2.5 μL, 4×) and NuPAGE® reducing agent (1.0 μL, 4×), and then left at room temperature for 10 min. The gel was run at 200 V constant for 35 min in 1× NuPAGE® MES SDS running buffer. The gel was fixed with H 2 O/MeOH/AcOH (50 : 42 : 8) for 1 h before being stained with Coomassie.
BCA protein assay
To determine the concentration of proteins, bicinchoninic acid protein assays (BCAs) were conducted by using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific) with diluted BSA as the standard. 5 μL of each sample and standard was pipetted into microplate wells. Then, 100 μL of the working reagent was added to each well. After being shaken at 37°C for 30 min, the absorbance was detected at 562 nm at room temperature by using a SpectraMax® i3x multi-mode microplate reader. A standard linear fitted curve was prepared by plotting the average blank-corrected measurement for each standard vs. its concentration using Prism (GraphPad software). Then the standard curve was used to determine the protein concentration of each sample.
Biotinylation of trastuzumab
To use SA biosensors to determine the K D , trastuzumab and stapled trastuzumab were conjugated to EZ-Link™ NHS-PEG 4 -Biotin (Thermo Fisher Scientific). To a solution of the corresponding protein (20 μL, 20 μM in PBS) was added the biotin linker (20 μL, 10 equiv., 200 μM in PBS). After being shaken at room temperature for 30 min, the non-reacted NHS-PEG 4 -Biotin was removed by diafiltration into PBS buffer by using Vivaspin 500 sample concentrators (5 min, 15 000g, GE Healthcare, 30 kDa MWCO).
Bio-layer interferometry
Binding assays were performed on an Octet® Red96 System (fortéBIO). Ligand immobilization, binding reactions, regeneration, and washes were conducted in wells of black polypropylene 96-well microplates. Fab, trastuzumab and the corresponding stapled compounds (20 nM) were immobilized on SA biosensors in PBS with 0.1% bovine serum albumin (BSA) and 0.02% tween at 30°C. Binding analyses were carried out at 25°C, 1000 rpm in PBS with 0.1% BSA and 0.02% tween, with 600 s of association followed by 2200 s of dissociation with different concentrations of the recombinant HER2 receptor to obtain the association curve. Glycine pH 2.0 was used as a regeneration buffer. Data were analysed by using Data Analysis (fortéBIO) with Savitzky-Golay filtering. Binding data were fitted to a 2 : 1 heterogeneous ligand model, and steady state analysis was performed to obtain the binding constant (K D ).
Circular dichroism
The secondary structures of native and stapled trastuzumab were determined by CD spectroscopy. The purified antibodies were dissolved in PBS at the final concentration of 0.4 mg mL −1 , and the CD spectra were recorded on a Jasco J-815 CD spectropolarimeter (Hachioji, Tokyo, Japan) by using quartz cuvettes of 0.1 mm (Hellma GmbH & Co, Müllheim, Germany). Temperature scans were measured at 25, 37, 55, 75 and 80°C. Temperature regulation was carried out with a PTC-348WI thermocouple (JASCO). In the 190 to 260 nm wavelength region, 5 or 10 scans were accumulated with a sampling velocity of 200 nm min −1 , a data pitch of 0.5 nm, a data integration time of 1 s, and 1 nm bandwidth. The signal from the buffer blank was subtracted from the sample scan and the experimental instrument-related baseline drift was corrected by subtracting the average of the signal between 250 and 260 nm from each spectrum.
Differential scanning fluorimetry (DSF)
The experiment was performed by using a 7500 Fast Real Time PCR System (Applied Biosystems, Warrington, Cheshire, U.K.), with an excitation range of 510-530 nm and the samples were subjected to the heating cycle as described previously. 19a Briefly, 2 μL of native and stapled trastuzumab at an initial concentration of 7.6 μM were mixed with a fresh dilution of SYPRO Orange® (Invitrogen) and diluted PBS to a final volume of 25 μL. A PCR plate was kept on ice during the preparation to prevent protein denaturation and to equilibrate the sample for the starting temperature of the assay. The measurements were performed in triplicate. The fluorescence emission signal at 567-596 nm was used for data analysis.
Cell culturing and flow cytometry studies
Human Burkitt Lymphoma cells (RAJI), HPB-ALL and breast cancer cells (SKBR3) were routinely cultured at 37°C with 5% CO 2 in RPMI-1640 and or DMEM medium supplemented with 10% (v/v) heat inactivated fetal bovine serum and 2 mM L-glutamine. Binding of stapled and native Rituximab and Trastuzumab antibodies to the surface CD-20 and HER2 receptors was analysed by flow cytometry. In brief, the cells were incubated with the respective stapled and native antibodies at 4°C for 30 min. The cells were then washed with ice-cold PBS and the primary antibody was detected by using a commercial Goat Alexa 647-conjugated anti-human (H + L) antibody (Thermo Fisher Scientific). Samples were acquired with a FACS Fortessa I/II (BD Bioscience) and analysed with FlowJo (Tree Star). All the primary PBMC cells and human plasma were obtained at Instituto de Medicina Molecular and Hospital Santa Maria under medical supervision. Peripheral blood was drawn into heparin coated tubes (BD) and processed at room temperature (RT). PBMCs were isolated by Ficoll-Paque gradient centrifugation.
Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cellular cytotoxicity (CDC)
The ADCC assay was performed by using fresh PBMCs from a healthy volunteer. In brief, the target Burkitt lymphoma cells (RAJI) were stained with Calcein-AM (Molecular Probes) at a concentration of 2 μM per 1 × 10 6 cells, at 37°C for 30 min in phenol red free RPMI medium. Cells were thoroughly washed and incubated with PBMCs at an effector : target ratio of 50 : 1 in the presence and absence of the respective antibodies for 4 h at 37°C, 5% CO 2 in 96-well round-bottom plates. After the incubation time, the plates were centrifuged and 100 μL of the supernatant was transferred and the fluorescence was read at an excitation wavelength of 485 nm and an emission wavelength of 520 nm. The percentage of cytotoxicity was calculated by using the following formula: % dead cells ¼ ÂÀ Experimental release À Spontaneous releaseÞ= À Maximal release À Spontaneous release ÁÃ Â 100
wherein the maximal release was triggered by the addition of 4% Triton-X. CDC cells were incubated with 10% normal human serum for a period of 24 h and the assay was developed as mentioned in the ADCC methodology.
Antibody pharmacokinetics in vivo
NOD SCID mice of age 8-12 weeks (n = 12 per group; n = 4 per time points per group) were administered a 5 mg kg −1 I.V bolus injection of the native and the stapled trastuzumab antibody. Blood was collected at the selected time points for up to 28 days. Blood samples were processed to collect plasma at the aforementioned time points and stored at −80°C until further processing. The total antibody concentration in plasma was determined by ELISA against recombinant HER2 protein. All protocols and animal procedures were approved by the Institutional Animal Ethics committee of Instituto de Medicina Molecular and followed the recommendations for the care and use of laboratory animals by European commission and Portuguese authorities. The NOD-SCID strain of mice was obtained from Charles River Laboratories and housed in a specific pathogen-free facility at the Instituto de Medicina Molecular (Lisbon, Portugal). All mice were 8-12 weeks old.
Statistical analysis
Data were analyzed using GraphPad Prism (version 6.01; GraphPad software). Statistical analysis was performed using Student's t-test or Mann-Whitney test, with Bonferroni posttests, Log-rank or Gehan-Breslow-Wilcoxon tests, or 2-way ANOVA, as appropriate. Differences were considered significant for p < 0.05.
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